Full-Time

Sr. Manager

Info. Gov. & Stewardship

Posted on 6/13/2026

Deadline 6/15/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$122k - $245k/yr

West Chester, PA, USA + 3 more

More locations: Bridgewater Township, NJ, USA | Cork, Ireland | Bridgewater, MA, USA

Hybrid

Category
Data & Analytics (1)
Required Skills
Collibra
Informatica
Data Governance
Data Analysis
Requirements
  • Bachelor’s degree in Information Systems, Supply Chain, Business, Engineering, or related field.
  • 8–10+ years of progressive experience in information governance, data governance, master data, supply chain systems, or related enterprise data and operations roles.
  • Demonstrated success designing and operationalizing governance frameworks, stewardship models, data quality controls, and decision rights across complex, cross-functional organizations.
  • Proven leadership experience in global or matrixed environments, including influencing senior stakeholders and driving alignment across business and technology teams.
  • Strong knowledge of supply chain and enterprise platforms, including ERP, planning, manufacturing, logistics, warehouse, quality, and analytics systems, and the data dependencies across them.
  • Strong understanding of data governance, master data management, metadata, information lifecycle management, and internal control concepts.
  • Ability to translate complex data, process, and system issues into clear business implications, prioritized actions, and executive-level recommendations.
  • Experience with enterprise data governance and catalog tools (Colibra, Informatica, Alation, Microsoft Purview, etc.).
  • Familiarity with data privacy and regulatory frameworks including GxP, SOX.
Responsibilities
  • Define and execute the global information governance and data stewardship for SC&O systems, aligning priorities, controls, and operating models with enterprise standards, business objectives, and regulatory expectations.
  • Establish and sustain clear data ownership, stewardship, decision rights, and accountability across critical supply chain data domains, supported by effective governance forums, escalation paths, and performance expectations.
  • Partner across Supply Chain, IT, Quality, Regulatory, Compliance, Security, and Data & Analytics to standardize business definitions, strengthen master and transactional data integrity, and improve end-to-end data lifecycle management.
  • Lead governance requirements for system implementations, process redesign, and platform integrations, ensuring data quality, traceability, compliance, and controls are embedded by design across digital supply chain initiatives.
  • Holistic focus on master data and the data creation processes, including master data management (processes, data quality tests, reports and workflows), and interfaces.
  • Work in collaboration with the E2E Data Leads on the ERP Deployment Teams to ensure documentation, development, testing and delivery follow DePuy Synthes ERP program delivery methodology where relevant to Master Data objects.
  • Advance AI- and automation-enabled governance capabilities, including intelligent monitoring, exception-based workflows, data quality rule automation, and advanced analytics to improve speed, scale, and risk visibility.
  • Define, monitor, and communicate governance, data quality, and compliance KPIs to senior leadership, using insights to prioritize remediation, measure maturity, and accelerate continuous improvement.
  • Build and develop a high-performing information governance and stewardship team while influencing cross-functional stakeholders and fostering a culture of data ownership, discipline, and operational excellence.
  • Maintain data lineage, retention schedules, and archiving policies for master data in alignment with legal and audit requirements
  • Collaborate with Legal, Regulatory, Compliance, IT and Security to ensure ERP access controls, segregation of duties, and data classification policies are enforced.
  • Serve as a senior advisor to Supply Chain leadership on information risk, inspection and audit readiness, and the operational impact of data and process changes, ensuring robust documentation, controls, and traceability.
Desired Qualifications
  • Advanced degree (MBA, Master’s, or equivalent) with concentration in data, supply chain, operations, analytics, technology management, or related discipline.
  • Experience in medical devices, life sciences, healthcare, or other highly regulated manufacturing environments.
  • Knowledge of global regulatory, privacy, records management, and compliance requirements relevant to supply chain data, quality systems, and controlled business processes.
  • Experience supporting digital transformation, data modernization, or enterprise platform initiatives with governance embedded into process and system design.
  • Exposure to AI, advanced analytics, automation, or intelligent workflow capabilities used to improve data quality, stewardship efficiency, control effectiveness, or risk monitoring.
  • Experience working across global operating models, including collaboration across regions, functions, and time zones.
  • Strong executive presence, change leadership, and cross-functional collaboration skills, with the ability to lead through influence in complex organizations.
  • Experience with SAP and JDE ERPs, Particularly S4 Hana.
  • English required; additional languages are a plus.
  • Travel: Up to 15–20%, domestic and international.
  • Certifications (Preferred): Data Governance, Information Management, or Supply Chain certifications.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Your Connections

People at Johnson & Johnson who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Firefly Bio expands J&J's KRAS-focused oncology platform for hard-to-treat tumors.
  • TREMFYA, CARVYKTI, and RYBREVANT are offsetting STELARA's biosimilar decline.
  • Jacksonville and Pennsylvania investments deepen manufacturing capacity and support future growth.

What critics are saying

  • STELARA's biosimilar erosion continues to pressure immunology revenue until replacements scale.
  • Talc litigation remains a recurring cash, reserve, and reputational overhang.
  • Firefly Bio's clinical-stage assets face efficacy risk before meaningful oncology contribution.

What makes Johnson & Johnson unique

  • J&J combines pharmaceuticals, MedTech, and consumer health across global markets.
  • Its 2026 pipeline spans oncology, immunology, neuroscience, and cardiovascular programs.
  • AAA credit and 64 straight dividend increases signal exceptional financial durability.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-11%

1 year growth

-11%

2 year growth

-10%
Johnson & Johnson
Jun 8th, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

INACTIVE